Adial Pharmaceuticals Inc. | Addiction Drug Developer Adial Pharmaceuticals Successfully Passes Patent Opposition Period in Europe for AD04 in Alcohol Use Disorder; Reports No Challenges to European Patent
16229
post-template-default,single,single-post,postid-16229,single-format-link,ajax_fade,page_not_loaded,,qode-theme-ver-16.2.1,qode-theme-bridge,disabled_footer_top,wpb-js-composer js-comp-ver-5.5.4,vc_responsive

Addiction Drug Developer Adial Pharmaceuticals Successfully Passes Patent Opposition Period in Europe for AD04 in Alcohol Use Disorder; Reports No Challenges to European Patent